OOIR: Observatory of International Research

Papers

(The H4-Index of Epilepsia is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions	257
ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions	233
New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study	210
The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures	151
ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions	149
Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune‐associated epilepsy: Conceptual definitions	136
The SANTÉ study at 10 years of follow‐up: Effectiveness, safety, and sudden unexpected death in epilepsy	130
A new era in electroencephalographic monitoring? Subscalp devices for ultra–long‐term recordings	111
Severe psychological distress among patients with epilepsy during the COVID‐19 outbreak in southwest China	103
Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study	99
The ILAE consensus classification of focal cortical dysplasia: An update proposed by an ad hoc task force of the ILAE diagnostic methods commission	89
Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions	86
International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions	81
COVID‐19 outbreak: The impact of stress on seizures in patients with epilepsy	75
Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability: A systematic review and meta‐analysis	75
Real‐world experience with direct brain‐responsive neurostimulation for focal onset seizures	75
Machine learning from wristband sensor data for wearable, noninvasive seizure forecasting	73
Epilepsy and brain network hubs	67
Cannabidiol efficacy and clobazam status: A systematic review and meta‐analysis	66
Machine learning and wearable devices of the future	63
International consensus on diagnosis and management of Dravet syndrome	62
Functional connectome contractions in temporal lobe epilepsy: Microstructural underpinnings and predictors of surgical outcome	60
Use of ketogenic diet therapy in infants with epilepsy: A systematic review and meta‐analysis	59
Value of 7T MRI and post‐processing in patients with nonlesional 3T MRI undergoing epilepsy presurgical evaluation	59
The accuracy of using administrative healthcare data to identify epilepsy cases: A systematic review of validation studies	59

Seizure detection at home: Do devices on the market match the needs of people living with epilepsy and their caregivers?	58
Continuous EEG findings in patients with COVID‐19 infection admitted to a New York academic hospital system	57
Seizure detection using wearable sensors and machine learning: Setting a benchmark	56
Orbitofrontal involvement in a neuroCOVID‐19 patient	56
The postictal state — What do we know?	55
Utility of genetic testing for therapeutic decision‐making in adults with epilepsy	55
COVID‐19 and seizures: Is there a link?	55
Comparison of minimally invasive and traditional surgical approaches for refractory mesial temporal lobe epilepsy: A systematic review and meta‐analysis of outcomes	55
Toward a better definition of focal cortical dysplasia: An iterative histopathological and genetic agreement trial	54
Genetic testing for the epilepsies: A systematic review	52
Deep brain stimulation targets in epilepsy: Systematic review and meta‐analysis of anterior and centromedian thalamic nuclei and hippocampus	52
Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial	51
Trait and state interoceptive abnormalities are associated with dissociation and seizure frequency in patients with functional seizures	50
Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [¹¹C]UCB‐J positron emission tomography study	50
Defining Dravet syndrome: An essential pre‐requisite for precision medicine trials	50
Connectome biomarkers of drug‐resistant epilepsy	49
Seizure forecasting and cyclic control of seizures	49
Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress	49
Post–COVID‐19 inflammatory syndrome manifesting as refractory status epilepticus	48
Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology	47
Epilepsy care during the COVID‐19 pandemic	47
Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy	46
Cognitive phenotypes in temporal lobe epilepsy utilizing data‐ and clinically driven approaches: Moving toward a new taxonomy	46